In November 2019, Advent International had acquired a 74 percent stake in Bharat Serums from its erstwhile private equity investors Orbimed Asia and Kotak PE, as well as the promoters of the company, the Daftary family, for around $500 million. Later, the PE fund acquired the family s remaining 26% stake.
Suven Pharmaceuticals is a listed CDMO and Cohance Lifesciences is an unlisted API and CDMO platform. Both are part of private equity firm Advent International s India portfolio.
In banking and financial services, power utilities, metals and mining etc, companies from the private sector could provide better growth and profitability outcomes versus the PSU sector over the medium to long term, says Ajay Tyagi of UTI AMC.
Advent International, which had $95 billion in assets under management as of March 2023, focuses on investments in five core sectors: business and financial services, healthcare, industrial, retail, consumer and leisure, and technology.
In November 2019, Advent announced the buyout of a controlling stake in the company, providing a complete exit to the erstwhile investors, Orbimed Asia and Kotak PE. A partial exit was given to the founders, the Daftary family.